![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Prostate Cancer |
Free Subscription
1 BJU Int |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
LUNAR: a randomized phase 2 study of (177) Lutetium-PSMA neoadjuvant to ablative
radiotherapy for oligorecurrent prostate cancer (clinical trial protocol).
BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988.
PubMed
Abstract available
Racial inequities in the quality of surgical care among Medicare beneficiaries
with localized prostate cancer.
Cancer. 2023 Feb 13. doi: 10.1002/cncr.34681.
PubMed
Abstract available
Bayesian machine learning enables identification of transcriptional network
disruptions associated with drug-resistant prostate cancer.
Cancer Res. 2023 Feb 13:CAN-22-1910. doi: 10.1158/0008-5472.CAN-22-1910.
PubMed
Abstract available
Stimulated Raman Scattering Microscopy Enables Gleason Scoring of Prostate Core
Needle Biopsy by a Convolutional Neural Network.
Cancer Res. 2023;83:641-651.
PubMed
Abstract available
Deregulation of SPOP in Cancer.
Cancer Res. 2023;83:489-499.
PubMed
Abstract available
Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of
Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?
Eur Urol. 2023 Feb 9:S0302-2838(23)02565-4. doi: 10.1016/j.eururo.2023.
PubMed
Abstract available
Re: Sigrid V. Carlsson, Rebecka Arnsrud Godtman, Carl-Gustav Pihl, et al. Young
Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater
Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg
Randomized Populat
Eur Urol. 2023 Feb 9:S0302-2838(23)02562-9. doi: 10.1016/j.eururo.2022.
PubMed
Re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced
Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed
Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80.
Eur Urol. 2023 Feb 9:S0302-2838(23)02563-0. doi: 10.1016/j.eururo.2022.
PubMed
Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
Eur Urol. 2023 Feb 11:S0302-2838(23)02567-8. doi: 10.1016/j.eururo.2023.
PubMed
Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio
Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom
Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for
Patients with Newly D
Eur Urol. 2023 Feb 11:S0302-2838(23)02564-2. doi: 10.1016/j.eururo.2023.
PubMed
Re: Sensitivity of Multiparametric MRI and Targeted Biopsy for Detection of
Adverse Pathologies (Cribriform Gleason Pattern 4 and Intraductal Carcinoma):
Correlation of Detected and Missed Prostate Cancer Foci with Whole Mount
Histopathology.
Eur Urol. 2023 Feb 13:S0302-2838(23)02573-3. doi: 10.1016/j.eururo.2023.
PubMed
Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of
Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated
with Salvage Lymph Node Dissection via Prostate-specific Membrane
Antigen-radioguided Surge
Eur Urol. 2023 Feb 14:S0302-2838(23)02583-6. doi: 10.1016/j.eururo.2023.
PubMed
Zinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate
cancer.
Int J Oncol. 2023;62:38.
PubMed
Abstract available
Omitting routine cystography after RARP: Analysis of complications and
readmission rates in suprapubic and transurethral drained patients.
Int J Urol. 2023;30:211-218.
PubMed
Abstract available
Stroma biglycan expression can be a prognostic factor in prostate cancers.
Int J Urol. 2023;30:147-154.
PubMed
Abstract available
T2 Turbo Spin Echo With Compressed Sensing and Propeller Acquisition (Sampling
k-Space by Utilizing Rotating Blades) for Fast and Motion Robust Prostate MRI:
Comparison With Conventional Acquisition.
Invest Radiol. 2023;58:209-215.
PubMed
Abstract available
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic
Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the
Phase III ARASENS Trial.
J Clin Oncol. 2023 Feb 16:JCO2300041. doi: 10.1200/JCO.23.00041.
PubMed
Abstract available
The Role of Physician Specialty in the Underutilization of Standard-of-Care
Treatment Intensification in Patients with Metastatic Castration-Sensitive
Prostate Cancer.
J Urol. 2023 Feb 15:101097JU0000000000003370. doi: 10.1097/JU.0000000000003370.
PubMed
Abstract available
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676.
PubMed
Abstract available
Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion.
N Engl J Med. 2023;388:660-662.
PubMed
GHR expression and prostate cancer proliferation.
Nat Rev Urol. 2023 Feb 13. doi: 10.1038/s41585-023-00740.
PubMed
PARP inhibitor response in prostate cancer.
Nat Rev Urol. 2023 Feb 10. doi: 10.1038/s41585-023-00735.
PubMed
Preclinical models of prostate cancer - modelling androgen dependency and
castration resistance in vitro, ex vivo and in vivo.
Nat Rev Urol. 2023 Feb 14. doi: 10.1038/s41585-023-00726.
PubMed
Abstract available
[Corrigendum] Long non‑coding RNA AC245100.4 promotes prostate cancer
tumorigenesis via the microRNA‑145‑5p/RBBP5 axis.
Oncol Rep. 2023;49:62.
PubMed
Abstract available
ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis.
Prostate. 2023 Feb 15. doi: 10.1002/pros.24495.
PubMed
Abstract available
Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Prostate. 2023 Feb 13. doi: 10.1002/pros.24497.
PubMed
Abstract available
Visual Analogue Scale (VAS) in the Evaluation of Functional Outcomes After
Three-dimensional Laparoscopic Prostatectomy.
Urology. 2023;172:121-125.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by